Swedish orthobiologics company Bonesupport is seeking to raise SEK500m ($45m) by floating its shares publicly for the first time on the Nasdaq Stockholm stock exchange. Proceeds from the IPO will go towards advancing sales of its existing bone substitute products and conducting a major study to gain US approval of antibiotic-eluting bone filler Cerament G.

BioCeramic Therapeutics was formed around separate regenerative medicine technologies that it believes have broad potential. First up is a strontium containing glass-based material for use as a bone filler and a coating for metal implants used in various orthopedic and orthodontic procedures. The company is also developing a nanostructured synthetic extracellular matrix that could address the regeneration of hard and soft tissues, with the potential one day to allow almost any tissue to be grown.